A compound having the structure of Formula (I): wherein: is; each R 1 is independently selected from C 2-6 alkynyl, C 1-6 alkyl-OR 7 , C 3-8 cycloalkyl, -NR 5 R 6 , OR 7 , -SO 2 R 12 , -SF 5 , -SR 8 , aryl, and heteroaryl, wherein aryl and heteroaryl are substituted with one or two groups independently selected from -C(O)NR 8 R 9 ; or two adjacent R 1 form a heterocycloalkyl ring optionally substituted with one or two R 11 ; R 2 is C 1-6 alkyl; R 3 is selected from halogen, -CN, C 1-6 alkyl, C 1-6 haloalkyl, -NR 8 R 9 , -C(O)NR 8 R 9 , -NR 8 C(O)R 9 , and -NR 9 SO 2 R 8 ; R 3a is selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 4 is independently selected from H and C 1-6 alkyl; each R 5 and R 6 is independently selected from H, C 1-6 alkyl, and C 3-8 cycloalkyl; or R 5 and R 6 , together with the nitrogen to which they are attached, form a heterocycloalkyl optionally substituted with one or two R 10 ; each R 7 is independently selected from H, C 1-6 alkyl-O-C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one or two groups independently selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 8 and R 9 is independently selected from H, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and heteroaryl; each R 10 is independently selected from C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, halogen, oxo, -CN, -C(O)OR 8 , -C(O)R 8 , -C(O)NR 8 R 9 , -SO 2 R 8 , -NR 9 C(O)R 8 , and -NR 9 SO 2 R 8 ; each R 11 is independently selected from halogen and C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl and C 3-8 cycloalkyl; m is 1, 2, 3, 4, or 5; p is 1; and q is 0 or 1; or a pharmaceutically acceptable salt, solvate, isotopically-labeled form or stereoisomer thereof. each R 1 is independently selected from C 2-6 alkynyl, C 1-6 alkyl-OR 7 , C 3-8 cycloalkyl, -NR 5 R 6 , OR 7 , -SO 2 R 12 , -SF 5 , -SR 8 , aryl, and heteroaryl, wherein aryl and heteroaryl are substituted with one or two groups independently selected from -C(O)NR 8 R 9 ; or two adjacent R 1 form a heterocycloalkyl ring optionally substituted with one or two R 11 ; R 2 is C 1-6 alkyl; R 3 is selected from halogen, -CN, C 1-6 alkyl, C 1-6 haloalkyl, -NR 8 R 9 , -C(O)NR 8 R 9 , -NR 8 C(O)R 9 , and -NR 9 SO 2 R 8 ; R 3a is selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 4 is independently selected from H and C 1-6 alkyl; each R 5 and R 6 is independently selected from H, C 1-6 alkyl, and C 3-8 cycloalkyl; or R 5 and R 6 , together with the nitrogen to which they are attached, form a heterocycloalkyl optionally substituted with one or two R 10 ; each R 7 is independently selected from H, C 1-6 alkyl-O-C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one or two groups independently selected from halogen, C 1-6 alkyl, and C 1-6 haloalkyl; each R 8 and R 9 is independently selected from H, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, and heteroaryl; each R 10 is independently selected from C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, halogen, oxo, -CN, -C(O)OR 8 , -C(O)R 8 , -C(O)NR 8 R 9 , -SO 2 R 8 , -NR 9 C(O)R 8 , and -NR 9 SO 2 R 8 ; each R 11 is independently selected from halogen and C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl and C 3-8 cycloalkyl; m is 1, 2, 3, 4, or 5; p is 1; and q is 0 or 1; or a pharmaceutically acceptable salt, solvate, isotopically-labeled form or stereoisomer thereof. <EOS>